Mi Yang

Mi Yang

Auto-generated profile, based on publicly available information

Mi Yang

RWTH Aachen University

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2019 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
YLYansheng Liu
Yansheng Liu
YMYang Mi
Yang Mi
TMTorsten Mueller
Torsten Mueller
SKSaskia Kreibich
Saskia Kreibich
EWEvan G. Williams
Evan G. Williams
RARuedi Aebersold
Ruedi Aebersold

1 August 2017 in Cell Reports
Verified
Journal Article
Open access
TRTheodoros I. Roumeliotis
Theodoros I. Roumeliotis
SWSteven P. Williams
Steven P. Williams
EGEmanuel Gonçalves
Emanuel Gonçalves
CAClara Alsinet
Clara Alsinet
MVMartin Del Castillo Velasco-Herrera
Martin Del Castillo Velasco-Herrera
JCJyoti S. Choudhary
Jyoti S. Choudhary
Assessing the impact of genomic alterations on protein networks is fundamental in identifying the mechanisms that shape cancer heterogeneity. We have used isobaric labeling to characterize the proteomic landscapes of 50 colorectal cancer cell lines and to decipher the functional consequences of somatic genomic variants. The robust quantification of over 9,000 proteins and 11,000 phosphopeptides on average enabled the de novo construction of a functional protein correlation network, which ultimately exposed the collateral effects of mutations on protein complexes. CRISPR-cas9 deletion of key chromatin modifiers confirmed that the consequences of genomic alterations can propagate through protein interactions in a transcript-independent manner. Lastly, we leveraged the quantified proteome to perform unsupervised classification of the cell lines and to build predictive models of drug response in colorectal cancer. Overall, we provide a deep integrative view of the functional network and the molecular structure underlying the heterogeneity of colorectal cancer cells.

2 June 2020 in npj Systems Biology and Applications
Verified
Journal Article
Open access
PDF file
MYMi Yang
Mi Yang
PJPatricia Jaaks
Patricia Jaaks
JDJonathan Dry
Jonathan Dry
MGMathew Garnett
Mathew Garnett
MMMichael P. Menden
Michael P. Menden
JSJulio Saez-Rodriguez
Julio Saez-Rodriguez
Drug combinations can expand therapeutic options and address cancer’s resistance. However, the combinatorial space is enormous precluding its systematic exploration. Therefore, synergy prediction strategies are essential. We here present an approach to prioritise drug combinations in high-throughput screens and to stratify synergistic responses. At the core of our approach is the observation that the likelihood of synergy increases when targeting proteins with either strong functional similarity or dissimilarity. We estimate the similarity applying a multitask machine learning approach to basal gene expression and response to single drugs. We tested 7 protein target pairs (representing 29 combinations) and predicted their synergies in 33 breast cancer cell lines. In addition, we experimentally validated predicted synergy of the BRAF/insulin receptor combination (Dabrafenib/BMS-754807) in 48 colorectal cancer cell lines. We anticipate that our approaches can be used for prioritization of drug combinations in large scale screenings, and to maximize the efficacy of drugs already known to induce synergy, ultimately enabling patient stratification.

29 May 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MYMi Yang
Mi Yang
JSJaak Simm
Jaak Simm
CLChi Chung Lam
Chi Chung Lam
PZPooya Zakeri
Pooya Zakeri
GWGerard Van Westen
Gerard Van Westen
JSJulio Saez-Rodriguez
Julio Saez-Rodriguez
Despite the abundance of large-scale molecular and drug-response data, the insights gained about the mechanisms underlying treatment efficacy in cancer has been in general limited. Machine learning algorithms applied to those datasets most often are used to provide predictions without interpretation, or reveal single drug-gene association and fail to derive robust insights. We propose to use Macau, a bayesian multitask multi-relational algorithm to generalize from individual drugs and genes and explore the interactions between the drug targets and signaling pathways’ activation. A typical insight would be: “Activation of pathway Y will confer sensitivity to any drug targeting protein X”. We applied our methodology to the Genomics of Drug Sensitivity in Cancer (GDSC) screening, using gene expression of 990 cancer cell lines, activity scores of 11 signaling pathways derived from the tool PROGENy as cell line input and 228 nominal targets for 265 drugs as drug input. These interactions can guide a tissue-specific combination treatment strategy, for example suggesting to modulate a certain pathway to maximize the drug response for a given tissue. We confirmed in literature drug combination strategies derived from our result for brain, skin and stomach tissues. Such an analysis of interactions across tissues might help target discovery, drug repurposing and patient stratification strategies.

1 May 2020 in Cell Systems
Verified
Journal Article
Open access
HNHanna Najgebauer
Hanna Najgebauer
MYMi Yang
Mi Yang
HFHayley E. Francies
Hayley E. Francies
CPClare Pacini
Clare Pacini
ESEuan A. Stronach
Euan A. Stronach
Francesco IorioFrancesco Iorio
Francesco Iorio
Selecting appropriate cancer models is a key prerequisite for maximizing translational potential and clinical relevance of in vitro oncology studies. We developed CELLector: an R package and R Shiny application allowing researchers to select the most relevant cancer cell lines in a patient-genomic-guided fashion. CELLector leverages tumor genomics to identify recurrent subtypes with associated genomic signatures. It then evaluates these signatures in cancer cell lines to prioritize their selection. This enables users to choose appropriate in vitro models for inclusion or exclusion in retrospective analyses and future studies. Moreover, this allows bridging outcomes from cancer cell line screens to precisely defined sub-cohorts of primary tumors. Here, we demonstrate the usefulness and applicability of CELLector, showing how it can aid prioritization of in vitro models for future development and unveil patient-derived multivariate prognostic and therapeutic markers. CELLector is freely available at https://ot-cellector.shinyapps.io/CELLector_App/ (code at https://github.com/francescojm/CELLector and https://github.com/francescojm/CELLector_App).

25 November 2016 in Genome Medicine
Verified
Journal Article
Open access
PDF file
JDJonathan R. Dry
Jonathan R. Dry
MYMi Yang
Mi Yang
JSJulio Saez-Rodriguez
Julio Saez-Rodriguez
Combinations of therapies are being actively pursued to expand therapeutic options and deal with cancer’s pervasive resistance to treatment. Research efforts to discover effective combination treatments have focused on drugs targeting intracellular processes of the cancer cells and in particular on small molecules that target aberrant kinases. Accordingly, most of the computational methods used to study, predict, and develop drug combinations concentrate on these modes of action and signaling processes within the cancer cell. This focus on the cancer cell overlooks significant opportunities to tackle other components of tumor biology that may offer greater potential for improving patient survival. Many alternative strategies have been developed to combat cancer; for example, targeting different cancer cellular processes such as epigenetic control; modulating stromal cells that interact with the tumor; strengthening physical barriers that confine tumor growth; boosting the immune system to attack tumor cells; and even regulating the microbiome to support antitumor responses. We suggest that to fully exploit these treatment modalities using effective drug combinations it is necessary to develop multiscale computational approaches that take into account the full complexity underlying the biology of a tumor, its microenvironment, and a patient’s response to the drugs. In this Opinion article, we discuss preliminary work in this area and the needs—in terms of both computational and data requirements—that will truly empower such combinations.